Drugmaker Pfizer said on Monday that trials for its coronavirus vaccine are showing an efficacy rate of more than 90%.
The interim analysis looked at the first 94 confirmed cases of COVID-19 among the more than 43,000 volunteers who took the vaccine. Of those cases, only 10% were among those who had received a vaccine, while 90% of cases were among those who had received a placebo instead.
Pfizer said the vaccine, which requires two doses, had an efficacy rate higher than 90% at seven days after the second dose. The U.S. Food and Drug Administration said it would require more than 50% efficacy from a vaccine.
Pfizer CEO Albert Bourla said the vaccine was "the greatest medical advance" in the past hundred years.
"Emotions are very high. You can imagine how I felt when I heard the results yesterday at 2 p.m. I think that likely, based on impact, this will be the greatest medical advance in the last 100 years," Bourla said. "It is extraordinary but it's coming at a time that the world needs it the most."
Pfizer said it plans to seek emergency authorization from the FDA.
The United States currently has more than 9.8 million confirmed cases of the coronavirus, according to the Centers for Disease Control and Prevention. The country saw more than 93,000 new cases on Monday.